Visit Doctors
Visit
Visit
Call Doctors
Call
Call
Ask Doctors
Ask
Ask
Feed
Home
26 years
50 years old female had neuroendocrine cancer and it was removed by surgery.she is now under sandostatin's treatment, any precautions need to be taken? Is she gonna stay on this treatment for life?
Jul 24, 2014

Dr. Rania Mousa General Medicine
A neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional hormone-producing endocrine cells and nerve cells. Neuroendocrine cells are found throughout the body in organs such as the lungs and gastrointestinal tract, including the stomach and intestines.
people who have had surgery should be seen by their doctor three months after their operation for a physical examination, blood tests, and a CT scan. After that, follow-up care should include a physical examination and blood tests approximately every six to 12 months, with additional imaging studies, such as x-rays, as needed.
even that the patient had done surgery ,the risk for relapsing and developing is still present ,for that follow ups plans and certain medications will still present even after surgery ,protection is better than progressing of the cancer again
>it is encouraged to follow established guidelines for good health, such as maintaining a healthy weight, not smoking, eating a balanced diet, and having recommended cancer screening tests. Talk with your doctor to develop a plan that is best for your needs. Moderate physical activity can help rebuild your strength and energy level. Your doctor can help you create an appropriate exercise plan based upon your needs, physical abilities, and fitness level.
>AS for Sandostatin LAR(octereotid ) is a drug used to treat diarrhea and flushing associated with advanced carcinoid tumors and watery diarrhea associated with VIP (vasoactive intestinal polypeptide)–secreting tumors.
it is used because functioning tumors produce symptoms that are related to the oversecretion of hormones.
Patients treated with Sandostatin LAR remained free of cancer progression longer than
The greatest benefit of Sandostatin LAR was observed in patients with little or no tumor in the liver, and patients whose primary tumors had been surgically removed.
Sandostatin LAR may delay progression of metastatic neuroendocrine tumors of the midgut.
and it is a promising treatment option for patients following cytoreductive surgery with few remaining metastases
Follow the doctor rules to stabilize the patient progression of the disease ,don't stop the medication .
 •